Maze rolls out map to $131M IPO, as phase 2 kidney disease trial readies for dosing

cafead

Administrator
Staff member
  • cafead   Jan 28, 2025 at 10:42: AM
via Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a phase 2 trial.

article source